Robert Lorne Hopfner - SEC Form 4 Insider Trading Activity
Summary
Updated Aug 4, 2026
Robert Lorne Hopfner is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market purchases: $17K.
Profile
Robert Lorne Hopfner serves as Director of Evommune, Inc. (EVMN). Hopfner has also held reporting roles at Inozyme Pharma, Inc. (INZY). Hopfner has reported 4 insider filings with the SEC since 2025. The most recent filing was in December 2025.
| Role | Director, 10% Owner |
|---|---|
| Notability | 36/100 |
Board memberships
- Evommune, Inc.
- Inozyme Pharma, Inc.
Reported roles
- Director
Trading Pattern
InsiderAlpha's records for Robert Lorne Hopfner go back to 2025: 3 primary Form 4 filings, an average of 1.5 per year. The typical open-market purchase is $17K (1 buy totaling $17K). The largest single buy on record is $17K of EVMN in 2025. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Career & Filing History
Every role Robert Lorne Hopfner has reported on a Form 4, reconstructed from the filings themselves - reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
- Director, 10% Owner at Evommune, Inc. (EVMN) - 1 filing, 2025
- Insider at Evommune, Inc. (EVMN) - 1 filing, 2025
- Insider at Inozyme Pharma, Inc. (INZY) - 1 filing, 2025
Recent Transactions
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2025-12-22 | EVMN | Evommune, Inc. | P - Open-market purchase | 1.0K | $17.35 | $17K |
| 2025-11-12 | EVMN | Evommune, Inc. | J - Other acquisition / disposition | 294.5K | - | |
| 2025-11-12 | EVMN | Evommune, Inc. | J - Other acquisition / disposition | 1.63M | - | |
| 2025-11-12 | EVMN | Evommune, Inc. | J - Other acquisition / disposition | 1.44M | - | |
| 2025-11-12 | EVMN | Evommune, Inc. | J - Other acquisition / disposition | 3.0K | - | |
| 2025-07-01 | INZY | Inozyme Pharma, Inc. | J - Other acquisition / disposition | 1.57M | $4.00 | $6.29M |
| 2025-07-01 | INZY | Inozyme Pharma, Inc. | J - Other acquisition / disposition | 2.92M | $4.00 | $11.69M |
Most Active Insiders Right Now
Robert Lorne Hopfner has no recent co-filers at the same companies, so here are the insiders with the largest open-market activity across the market in the last 90 days.
- MetLife Investment Management, LLC - $1600000.00B of FINS open-market activity in the last 90 days
- Magnetar Financial LLC - $16357.48B of CRWV open-market activity in the last 90 days
- Marianne Okland - $18.46B of STNG open-market activity in the last 90 days
- VisionWave Holdings, Inc. - $14.13B of SVRE open-market activity in the last 90 days
- Vanessa Allen Sutherland - $7.44B of PSX open-market activity in the last 90 days
- AI Alpine (Luxembourg) S.a.r.l. - $2.69B of INIO open-market activity in the last 90 days
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
- Saul B. Rosenthal
- Jack Ross
- Martine A. Rothblatt
- Saba Capital Management, L.P.
- Nicholas S. Schorsch
- Trygve Seglem
- Lawrence B. Seidman
- Thomas J. Shaw
Frequently Asked Questions
Who is Robert Lorne Hopfner?
Robert Lorne Hopfner serves as Director of Evommune, Inc. (EVMN). Hopfner has also held reporting roles at Inozyme Pharma, Inc. (INZY). Hopfner has reported 4 insider filings with the SEC since 2025. The most recent filing was in December 2025.…
Has Robert Lorne Hopfner been buying or selling stock?
Recorded transactions: 1 open-market purchase ($17K) and 0 open-market sales across all tracked filings.
Where can I see all of Robert Lorne Hopfner's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Open the live Robert Lorne Hopfner profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.